Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Pancreatic Neoplasms 1HRD Cancer 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 104Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 46Nivolumab 41Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Irinotecan 21Capecitabine 19Leucovorin 18Fulvestrant 18Cetuximab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fluorouracil 17Docetaxel 17Bevacizumab 17Drug Therapy 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14Trastuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × berzosertib × 1 year × Clear all
NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡